JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1120/0.01/20.06.25 Share Price

Warrant

DE000JB9VNS9

Real-time Bid/Ask 11:37:11 05/07/2024 BST
0.84 EUR / 0.9 EUR +2.35% Intraday chart for JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1120/0.01/20.06.25
Current month-15.00%
1 month+25.00%
Date Price Change
05/07/24 0.85 0.00%
04/07/24 0.85 -10.53%
03/07/24 0.95 -6.86%
02/07/24 1.02 -1.92%
01/07/24 1.04 +4.00%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 08:21 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
Issuer J.P. Morgan
WKN JB9VNS
ISINDE000JB9VNS9
Date issued 04/01/2024
Strike 1,120 $
Maturity 20/06/2025 (351 Days)
Parity 100 : 1
Emission price 0.56
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.11
Lowest since issue 0.5
Delta0.5x
Omega 5.385
Premium18.67x
Gearing10.75x
Moneyness 0.9144
Difference Strike 95.91 $
Difference Strike %+8.56%
Spread 0.08
Spread %8.70%
Theoretical value 0.8700
Implied Volatility 27.63 %
Total Loss Probability 60.68 %
Intrinsic value 0.000000
Present value 0.8700
Break even 1,214.15 €
Theta-0.01x
Vega0.04x
Rho0.04x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,024 USD
Average target price
1,051 USD
Spread / Average Target
+2.67%
Consensus